Omnicell, Inc. (NASDAQ:OMCL) Shares Bought by Lazard Asset Management LLC

Lazard Asset Management LLC grew its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 81.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,641,817 shares of the company’s stock after buying an additional 737,536 shares during the quarter. Lazard Asset Management LLC’s holdings in Omnicell were worth $73,093,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after acquiring an additional 28,573 shares during the period. Dimensional Fund Advisors LP grew its holdings in Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after acquiring an additional 394,820 shares during the period. Victory Capital Management Inc. grew its holdings in Omnicell by 32.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after acquiring an additional 377,883 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after acquiring an additional 699,925 shares during the period. Finally, ArrowMark Colorado Holdings LLC grew its holdings in Omnicell by 4.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company’s stock worth $53,290,000 after acquiring an additional 56,117 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Up 6.5%

Shares of OMCL stock opened at $27.46 on Tuesday. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.75. The firm has a market cap of $1.29 billion, a PE ratio of 101.71, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The stock has a 50 day moving average of $32.08 and a 200-day moving average of $39.88. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Omnicell’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.03 earnings per share. On average, equities analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, May 3rd. Benchmark dropped their price target on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Wells Fargo & Company dropped their price target on Omnicell from $38.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Omnicell has an average rating of “Hold” and an average target price of $45.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.